Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Altamira TherapeuticsCYTOF +0.63% EV-to-EBITDA is -0.21 as of Aug. 19, 2026. The stock has 4 warning signs investors should review. Among 401 Biotechnology companies, Altamira Therapeutics ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Altamira Therapeutics's enterprise value is $1.15 Mil.
Altamira Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $-5.46 Mil. Therefore, Altamira Therapeutics's EV-to-EBITDA for today is -0.21.
The historical rank and industry rank for Altamira Therapeutics's EV-to-EBITDA or its related term are showing as below:
CYTOF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.21 Med: 0 Max: 0
Current: -0.21
CYTOF's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.6
vs CYTOF: -0.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Altamira Therapeutics's PE Ratio (TTM) for today is calculated as:
Altamira Therapeutics's share price for today is $0.064.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $-1.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Altamira Therapeutics EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Altamira Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CYTOF vs CARM, PTIX, SIGY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Altamira Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altamira Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Altamira Therapeutics's EV-to-EBITDA falls into.
Altamira Therapeutics's current Enterprise Value is $1.15 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2025 was $-5.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Altamira Therapeutics (CYTOF) has a EV-to-EBITDA of -0.21 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Altamira Therapeutics. According to the industry distribution chart, Altamira Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry.
Is Altamira Therapeutics' EV-to-EBITDA too high?
Altamira Therapeutics' current EV-to-EBITDA is -0.21. Based on the distribution chart, Altamira Therapeutics ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Altamira Therapeutics' EV-to-EBITDA compare to CARM and PTIX?
According to the Biotechnology industry distribution chart, Altamira Therapeutics ranks #999999 out of 401 companies for EV-to-EBITDA. This places Altamira Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.60, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Altamira Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Altamira Therapeutics's current EV-to-EBITDA is -0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altamira Therapeutics stock overvalued right now?
Altamira Therapeutics (CYTOF) has a current EV-to-EBITDA of -0.21. The current EV-to-EBITDA is -0.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Altamira Therapeutics (CYTOF), the current EV-to-EBITDA is -0.21 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Altamira Therapeutics Ltd is developing and supplying peptide-based nanoparticles for safe and effective RNA delivery to extrahepatic tissues (xPhore platform). The Company is offering biopharmaceutical companies access to its technology for use with their own RNA molecules under collaboration and licensing agreements. The xPhore platform is suitable for various RNA modalities - OligoPhore for oligonucleotides, SemaPhore for mRNA, CycloPhore for circRNA - as well as for DNA (GenePhore). In addition, Altamira Therapeutics is pursuing two proprietary flagship development programs using OligoPhore: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. Geographically, the companies operates in United Staes and Switzerland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CYTOF has been successfully added to your 
